Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease
- PMID: 25401511
- PMCID: PMC4399368
- DOI: 10.1001/jamaneurol.2014.2704
Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease
Abstract
Importance: Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of genetic Parkinson disease (PD) known to date. The clinical features of manifesting LRRK2 mutation carriers are generally indistinguishable from those of patients with sporadic PD. However, some PD cases associated with LRRK2 mutations lack Lewy bodies (LBs), a neuropathological hallmark of PD. We investigated whether the presence or absence of LBs correlates with different clinical features in LRRK2-related PD.
Observations: We describe genetic, clinical, and neuropathological findings of 37 cases of LRRK2-related PD including 33 published and 4 unpublished cases through October 2013. Among the different mutations, the LRRK2 p.G2019S mutation was most frequently associated with LB pathology. Nonmotor features of cognitive impairment/dementia, anxiety, and orthostatic hypotension were correlated with the presence of LBs. In contrast, a primarily motor phenotype was associated with a lack of LBs.
Conclusions and relevance: To our knowledge, this is the first report of clinicopathological correlations in a series of LRRK2-related PD cases. Findings from this selected group of patients with PD demonstrated that parkinsonian motor features can occur in the absence of LBs. However, LB pathology in LRRK2-related PD may be a marker for a broader parkinsonian symptom complex including cognitive impairment.
Similar articles
-
Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment.Acta Neuropathol. 2010 Aug;120(2):155-67. doi: 10.1007/s00401-010-0669-y. Epub 2010 Mar 16. Acta Neuropathol. 2010. PMID: 20232069
-
LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans.Arch Neurol. 2007 Mar;64(3):425-30. doi: 10.1001/archneur.64.3.425. Arch Neurol. 2007. PMID: 17353388
-
Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease.J Neuropathol Exp Neurol. 2010 Sep;69(9):959-72. doi: 10.1097/NEN.0b013e3181efc01c. J Neuropathol Exp Neurol. 2010. PMID: 20720502
-
[Clinical molecular genetics for PARK8 (LRRK2)].Brain Nerve. 2007 Aug;59(8):839-50. Brain Nerve. 2007. PMID: 17713120 Review. Japanese.
-
Clinical features of LRRK2 parkinsonism.Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S205-8. doi: 10.1016/S1353-8020(09)70815-6. Parkinsonism Relat Disord. 2009. PMID: 20082991 Review.
Cited by
-
LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson's Disease?Front Neurosci. 2020 Jun 17;14:577. doi: 10.3389/fnins.2020.00577. eCollection 2020. Front Neurosci. 2020. PMID: 32625052 Free PMC article. Review.
-
Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal.Transl Neurodegener. 2020 Oct 16;9(1):39. doi: 10.1186/s40035-020-00218-x. Transl Neurodegener. 2020. PMID: 33066808 Free PMC article. Review.
-
LRRK2 in Parkinson's disease: upstream regulation and therapeutic targeting.Trends Mol Med. 2024 Oct;30(10):982-996. doi: 10.1016/j.molmed.2024.07.003. Epub 2024 Aug 16. Trends Mol Med. 2024. PMID: 39153957 Review.
-
What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson's Disease Patients and Healthy Subjects with Parkinson's-Associated LRRK2 Mutations?J Parkinsons Dis. 2019;9(3):467-488. doi: 10.3233/JPD-191630. J Parkinsons Dis. 2019. PMID: 31322581 Free PMC article. Review.
-
Autophagy and LRRK2 in the Aging Brain.Front Neurosci. 2019 Dec 17;13:1352. doi: 10.3389/fnins.2019.01352. eCollection 2019. Front Neurosci. 2019. PMID: 31920513 Free PMC article. Review.
References
-
- Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol. 2002;51(3):296–301. - PubMed
-
- Ruiz-Martínez J, Gorostidi A, Ibañez B, et al. Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain). Mov Disord. 2010;25(14):2340–2345. - PubMed
-
- Goldwurm S, Tunesi S, Tesei S, et al. Kin-cohort analysis of LRRK2-G2019S penetrance in Parkinson's disease. Mov Disord. 2011;26(11):2144–2145. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P30 AG010124/AG/NIA NIH HHS/United States
- P01 AG 09215-20/AG/NIA NIH HHS/United States
- R01 NS078086/NS/NINDS NIH HHS/United States
- K02 NS080915/NS/NINDS NIH HHS/United States
- P01 AG009215/AG/NIA NIH HHS/United States
- P0412196-G/PHS HHS/United States
- NINDS NS36630/NS/NINDS NIH HHS/United States
- P50 NS038370/NS/NINDS NIH HHS/United States
- NINDS P50 NS053488-02/NS/NINDS NIH HHS/United States
- NIH/NINDS R01 NS078086/NS/NINDS NIH HHS/United States
- P01 AG017586/AG/NIA NIH HHS/United States
- NIA P30AG036468/AG/NIA NIH HHS/United States
- U01 AG024904/AG/NIA NIH HHS/United States
- P50 AG008702/AG/NIA NIH HHS/United States
- UL1 RR024156/RR/NCRR NIH HHS/United States
- NIA 1PO1 AG-19724-07/AG/NIA NIH HHS/United States
- NIH/NINDS P50 NS072187/NS/NINDS NIH HHS/United States
- P50 NS053488/NS/NINDS NIH HHS/United States
- NIA 1 U01 AG 024904-05/AG/NIA NIH HHS/United States
- RC1AG035427/AG/NIA NIH HHS/United States
- NIA P30 AG 10124-18/AG/NIA NIH HHS/United States
- P01 AG019724/AG/NIA NIH HHS/United States
- Canadian Institutes of Health Research/Canada
- NIA UO1 AG029213-01/AG/NIA NIH HHS/United States
- R01 NS060113/NS/NINDS NIH HHS/United States
- NS036630/NS/NINDS NIH HHS/United States
- P50 NS072187/NS/NINDS NIH HHS/United States
- NIH/NINDS P50 NS053488/NS/NINDS NIH HHS/United States
- R01 NS073872/NS/NINDS NIH HHS/United States
- U01 AG029213/AG/NIA NIH HHS/United States
- NINDS R01 NS073872/NS/NINDS NIH HHS/United States
- 1UL1 RR024156-01/RR/NCRR NIH HHS/United States
- R56 NS036630/NS/NINDS NIH HHS/United States
- NIA P50 AG 008702/AG/NIA NIH HHS/United States
- NINDS R01 NS060113/NS/NINDS NIH HHS/United States
- P30 AG036468/AG/NIA NIH HHS/United States
- U01 NS052592/NS/NINDS NIH HHS/United States
- R01 NS036630/NS/NINDS NIH HHS/United States
- P0412196- G/PHS HHS/United States
- RC2NS069368/NS/NINDS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical